A decade ago, most migraine preventives were pills repurposed from other conditions. Today, a wave of “new migraine shot” options—designed specifically for migraine biology—has changed the conversation. These injections don’t erase pain instantly, but they can trim monthly headache days, boost function, and offer convenient monthly or quarterly dosing for people across the United States.
Why Shots Changed Migraine Care
Injectable migraine treatments can target the condition more directly than older medications. The breakthrough came with therapies aimed at calcitonin gene–related peptide (CGRP), a neurochemical that rises during attacks and helps drive pain pathways. Instead of broadly dampening the nervous system, these drugs dial down a key migraine signal—one reason many patients report fewer or less intense episodes.
They’re also straightforward to use. Several options can be self-injected at home monthly, and some are dosed quarterly. For people juggling work, family, and unpredictable flare-ups, having a set schedule can feel like a small but meaningful relief. The big expectation to hold onto: these are primarily preventive therapies, so success is usually measured in fewer migraine days and fewer “rescue” meds—not immediate relief minutes after a dose.
How CGRP Injections Work
CGRP monoclonal antibodies include erenumab (which blocks the CGRP receptor) and ligand binders such as galcanezumab, fremanezumab, and eptinezumab. All aim to reduce the CGRP activity that can sensitize nerves and blood vessels during attacks, but they vary in delivery method and dosing schedules.
Aimovig (erenumab), Emgality (galcanezumab), and Ajovy (fremanezumab) are injected under the skin, typically monthly; Ajovy also has a quarterly dosing option. Vyepti (eptinezumab) is an IV infusion given in a clinic every three months. People often ask how soon a shot works: some notice early improvement within a few weeks, but many clinicians look for the fuller picture after two to three months.
Comparing Brands, Schedules, Costs
“Which one is best?” The honest answer is: it depends. In clinical trials, these medications show broadly similar prevention on average, with differences that often come down to side effects, dosing preferences, and practical access. Some people prefer an infusion every three months; others want the flexibility of self-injection at home.
Cost and coverage can be the deciding factor. Without insurance, per-dose costs can run hundreds of dollars, and infusion therapy can add facility and administration fees. Many US insurers require prior authorization, and criteria often include a confirmed migraine diagnosis, a minimum number of headache days per month, and prior trials (or intolerance) of other preventive medications. Copay cards or manufacturer assistance programs may reduce out-of-pocket costs for eligible patients.
It’s also common to compare notes online. Patient stories can be useful for questions to ask—but experiences vary widely, and what’s “life-changing” for one person can be underwhelming for another. If one option disappoints, switching within the CGRP class is routine in clinical practice, and some patients do better on one mechanism than another.
Effectiveness, Timelines, And Side Effects
What should you expect? Many studies report an average reduction of several monthly migraine days, depending on baseline severity and the group studied. For some, that means fewer lost workdays and fewer weekends written off; for others, the improvement is steadier and more modest. Clinicians commonly evaluate benefit after about three months, because early fluctuations can be misleading.
Do CGRP injections stop working over time? Some patients feel benefits fade after an initial strong response. Research hasn’t shown this to be a universal pattern, but migraine itself can change with stress, sleep disruption, hormonal shifts, or medication overuse. Possible next steps include adjusting timing, switching medications, or pairing prevention with behavioral and lifestyle supports.
On long-term safety, multi-year data are generally reassuring, but side effects happen. The most common are injection-site reactions; constipation is also reported, particularly with erenumab. Less commonly, people report muscle cramps, blood-pressure changes, or hypersensitivity reactions. Serious events are rare but possible, so clinicians weigh cardiovascular history and other risk factors. If you’re pregnant, trying to conceive, or breastfeeding, discuss this early—evidence is limited, and many experts recommend avoiding these medications in those periods.
Botox And Selecting Candidates
Botox (onabotulinumtoxinA) remains a proven option, especially for chronic migraine (15 or more headache days per month). The standard protocol uses multiple small injections across the head and neck about every 12 weeks. When comparing Botox with CGRP shots in chronic migraine, both can reduce headache days; the better fit often comes down to migraine pattern, past responses, and logistics.
How do doctors choose? They consider frequency, disability level, comorbidities, medication-overuse patterns, and patient preferences. Someone with episodic migraine and predictable monthly flares might prefer a self-injected preventive; someone with near-daily symptoms may be steered toward Botox—or, in selected cases, a combination approach if coverage allows. Practical details matter too: needle comfort, travel, infusion access, and out-of-pocket costs.
If you’re weighing options, bring a two- to three-month headache diary, a list of rescue meds you use, and any red flags you’ve noticed. That context helps tailor a plan that fits your life—not just your diagnosis.
Resources
[1] American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. *Headache*. 2021.
[2] Goadsby PJ et al. A Controlled Trial of Erenumab for Episodic Migraine. *N Engl J Med*. 2017.
[3] Stauffer VL et al. Galcanezumab in Episodic Migraine: EVOLVE Studies. *N Engl J Med*. 2018.
[4] Silberstein SD et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. *N Engl J Med*. 2017.
[5] Ashina M et al. Eptinezumab in Chronic Migraine (PROMISE‑2). *Lancet Neurol*. 2020.
[6] Aimovig (erenumab) Prescribing Information. U.S. FDA.
[7] Emgality (galcanezumab) Prescribing Information. U.S. FDA.
[8] Ajovy (fremanezumab) Prescribing Information. U.S. FDA.
[9] Vyepti (eptinezumab) Prescribing Information. U.S. FDA.
[10] Dodick DW et al. PREEMPT Clinical Program for OnabotulinumtoxinA in Chronic Migraine. *Cephalalgia*. 2010.